LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aandelen Lijst・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Gesloten

SectorGezondheidszorg

15.44 2.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.02

Max

15.49

Belangrijke statistieken
By Trading Economics
Inkomsten	-130B -25B
Verkoop	-99B 1.1T
K/W Sectorgemiddelde	39.974 49.888
EPS	0.21
Dividendrendement	4.35
Winstmarge	-2.222
Werknemers	47,455
EBITDA	-242B 214B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+39.72% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	4.35% 2.38%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3.7B 48B
Vorige openingsprijs	12.58
Vorige sluitingsprijs	15.44

Nieuwssentiment

By Acuity

100%

325 / 344 Rangschikking in Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 08:59 UTC

Winsten

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 jan 2026, 07:11 UTC

Winsten

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 dec 2025, 03:32 UTC

Belangrijke Marktbewegers

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 okt 2025, 09:39 UTC

Winsten

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 okt 2025, 07:32 UTC

Winsten

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 mei 2026, 06:57 UTC

Winsten

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 mei 2026, 06:54 UTC

Winsten

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 mei 2026, 06:44 UTC

Winsten

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 mei 2026, 06:38 UTC

Winsten

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 mei 2026, 06:31 UTC

Winsten

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 jan 2026, 06:53 UTC

Winsten

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 jan 2026, 06:36 UTC

Winsten

Takeda Raises FY Revenue, Net-Profit Views

29 jan 2026, 06:34 UTC

Winsten

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 jan 2026, 06:33 UTC

Winsten

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 jan 2026, 06:32 UTC

Winsten

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 okt 2025, 07:10 UTC

Winsten

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 okt 2025, 06:50 UTC

Winsten

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 okt 2025, 06:49 UTC

Winsten

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 okt 2025, 06:48 UTC

Winsten

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Peer Vergelijking

Prijswijziging

Takeda Pharmaceutical Co Ltd ADR Prognose

Koersdoel

By TipRanks

39.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21 USD 39.72%

Hoogste 21 USD

Laagste 21 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Takeda Pharmaceutical Co Ltd ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Takeda Pharmaceutical Co Ltd ADR - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.